Christine Stabell Benn

Biographic Data

ID7603777
NAMEChristine Stabell Benn
GIVEN NAMESChristine Stabell
FAMILY NAMEBenn
SIGNATUREBENN C S
AFFILIATIONSStatens Serum Institut
ORCID0000-0001-6102-3810
VERIFIEDYes
TOTAL WORKS10
TOTAL CITATIONS0
WORKS AS AUTHOR10
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2013
LATEST PUBLICATION YEAR2024
H-INDEX0

  • Can earlier BCG-Japan and OPV vaccination reduce early infant mortality? A cluster-randomised trial in Guinea-Bissau

    Open AccessSanne Marie Thysen, Igualdino Da Silva Borges et al.ARTICLEBMJ Global Health2024

    OBJECTIVE: To assess the effect of providing BCG and oral polio vaccine (OPV) at an early home visit after delivery. DESIGN: Cluster-randomised trial, randomising 92 geographically defined clusters 1:1 to intervention/control arms. SETTING: Bandim Health Project Health and Demographic Surveillance System, Guinea-Bissau. PARTICIPANTS: 2226 newborns enrolled between July 2016 and August 2019. INTERVENTIONS: In both arms, newborns received a home vi…

  • ‘It's not for the children's sake’

    Open AccessA Schneider-Kamp, Gareth Millward et al.ARTICLESSM - Qualitative Research in…2024

    Recently, the Danish Health Authority began recommending vaccinating children aged 2-6 years against seasonal influenza, underscoring the pivotal role of children in its transmission dynamics within the wider population and the need to protect vulnerable population groups after COVID-19. Under a third followed the recommendation. For the routine Danish childhood vaccine program coverage is usually well above 90%. Through a qualitative in-depth st…

  • One vaccine to counter many diseases? Modeling the economics of oral polio vaccine against child mortality and Covid-19

    Open AccessAlenda Y Chang, Peter Aaby et al.ARTICLEFrontiers in Public Health2022

    Introduction: Recent reviews summarize evidence that some vaccines have heterologous or non-specific effects (NSE), potentially offering protection against multiple pathogens. Numerous economic evaluations examine vaccines' pathogen-specific effects, but less than a handful focus on NSE. This paper addresses that gap by reporting economic evaluations of the NSE of oral polio vaccine (OPV) against under-five mortality and COVID-19. Materials and m…

  • The mortality effects of disregarding the strategy to save doses of measles vaccine

    Open AccessStine Byberg, Peter Aaby et al.ARTICLEBMJ Global Health2021

    INTRODUCTION: Measles vaccine (MV) may improve health beyond measles protection. To avoid wastage from multi-dose vials, children in Guinea-Bissau are only measles vaccinated when aged 9-11 months and when six or more children are present. We assessed health impacts of providing MV to all measles-unvaccinated children 9-35 months. METHODS: We cluster-randomised 182 village clusters under demographic surveillance in rural Guinea-Bissau to an 'MV-f…

  • Seasonal variation in the non-specific effects of BCG vaccination on neonatal mortality

    Open AccessKristoffer Jarlov Jensen, Sofie Biering-Sørensen et al.ARTICLEBMJ Global Health2020

    The BCG vaccine protects non-specifically against other diseases than tuberculosis. Three randomised controlled trials of early BCG in Guinea-Bissau found a 38% reduction in all-cause neonatal mortality. Little is known about the underlying mechanisms. In Guinea-Bissau, prevalent infectious diseases display distinct seasonality. Revisiting the three trials (>6500 infants) comparing early BCG versus no early BCG in low weight infants on all-cause …

  • BCG skin reactions by 2 months of age are associated with better survival in infancy

    Open AccessFrederik Schaltz‐Buchholzer, Mike Berendsen et al.ARTICLEBMJ Global Health2020

    INTRODUCTION: Receiving Bacille Calmette-Guérin (BCG)-Denmark vaccine at birth has been associated with ~40% reductions in all-cause neonatal mortality. We evaluated determinants of BCG skin reaction characteristics by age 2 months and tested the association with subsequent mortality. METHODS: Prospective observational study amalgamating five trials providing BCG-at-birth that were conducted between 2002 and 2018 in Guinea-Bissau. The reaction st…

  • Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau

    Open AccessStine Byberg, Ane Bærent Fisker et al.ARTICLEGlobal Health Action2017

    BACKGROUND: Measles vaccination is associated with major reductions in child mortality and morbidity. In Guinea-Bissau, to limit vaccine wastage, children are only measles-vaccinated if at least six children aged 9-11 months are present at a vaccination session. OBJECTIVE: To estimate the incremental cost-effectiveness of providing measles vaccine (MV) to all children regardless of age and number of children present. METHODS: We estimated MV cove…

  • The real-life number of neonatal doses of Bacille Calmette-Guérin vaccine in a 20-dose vial

    Open AccessFrederik Schaltz-Buchholzer, Frederik Schaltz‐Buchholzer et al.ARTICLEGlobal Health Action2017

    BACKGROUND: Reducing vaccine wastage is important. Bacille Calmette-Guérin (BCG) vaccine is produced in vials of 20 infant doses. The reconstituted vaccine is discarded after 4-6 hours. Therefore, to reduce vaccine wastage, a 20-dose vial of BCG is often only opened if at least 10-12 infants are present, jeopardising BCG vaccination coverage and timely vaccination. We observed that nurses were not able to withdraw 20 doses from the vials and aime…

  • BCG coverage and barriers to BCG vaccination in Guinea-Bissau

    Open AccessSanne Marie Thysen, Stine Byberg et al.ARTICLEBMC Public Health2014

    BCG coverage during the first months of life is low in Guinea-Bissau. Providing BCG at monthly vaccination visits removes the risk factors associated with delayed BCG vaccination

  • Determinants of vitamin a deficiency in children between 6 months and 2 years of age in Guinea-Bissau

    Open AccessNiels Banhos Danneskiold‐Samsøe, Niels Danneskiold-Samsøe et al.ARTICLEBMC Public Health2013

    Clinicaltrials.gov NCT00514891